CEPI and Samsung Biologics have partnered to strengthen global preparedness for vaccine production against pandemics and epidemics.[1][2] Samsung Biologics will join CEPI's Vaccine Manufacturing Facility Network (VMFN), becoming the first partner from East Asia.[1][2][3] The goal is to accelerate the availability of protein vaccines and ensure equitable access to them in low- and middle-income countries (LMICs) during future disease outbreaks.[1][2] The partnership supports an initial budget of up to US$20 million to establish a scalable and rapid manufacturing process for recombinant protein vaccines.[1][2][3] Samsung Biologics' infrastructure based on mammalian cells and their quality and regulatory systems will be used.[2][3] In the event of a pandemic, Samsung Biologics will provide CEPI with access to up to 50 million doses of vaccines and another billion doses of drug to produce finished vaccines.[1][3] This will ensure a buffer for vulnerable populations in LMICs while meeting Korea's national needs under CEPI's policy of equal access.[1][3] The partnership supports the CEPI 100 Days Mission to develop vaccines within 100 days of identifying a new pathogen.[1][2][3]